Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIa. 2020

Christoph Kannicht, and Ilona Danßmann, and Constanze Weilandt, and Katja Derkow, and Guido Kohla, and Henriette Geyer
Octapharma Biopharmaceuticals GmbH, Molecular Biochemistry, Walther-Nernst-Straße 3, 12489 Berlin, Germany.

This study compares the effect of recombinant Factor VIII Fc fusion protein (rFVIII-Fc) with recombinant FVIII (rFVIII) on monocyte-derived dendritic cells (moDC's). Cells treated with rFVIII-Fc showed morphological changes typical for cell activation, had a significant up-regulation of cell activation markers and produced higher levels of pro-inflammatory cytokines. Even after stimulation with Lipopolysaccharides, the addition of rFVIII-Fc led to increased expression of activation markers, indicating that rFVIII-Fc is capable of amplifying the maturation signal. On the contrary, cultivation of moDC's with rFVIII did not alter cell morphology or increase surface activation marker expression and pro-inflammatory cytokine production. The binding of the Fc domain to the activating Fcγ receptor IIa (FcγRIIa) can cause cell activation. Therefore, the effect of rFVIII-Fc on FcγRIIa was analyzed in detail. Cultivation of moDC's with rFVIII-Fc led to increased phosphorylation of FcγRIIa, which was not detected for rFVIII. Blocking FcγRIIa prior to the cultivation with rFVIII-Fc significantly reduced the activating effect of rFVIII-Fc, indicating that rFVIII-Fc-induced moDC activation was caused by FcγRIIa. Moreover, rFVIII-Fc bound to FCGR2A-transfected human embryonic kidney 293 cells. Taken together, our data present a new mechanism of moDC activation by rFVIII-Fc via FcγRIIa.

UI MeSH Term Description Entries

Related Publications

Christoph Kannicht, and Ilona Danßmann, and Constanze Weilandt, and Katja Derkow, and Guido Kohla, and Henriette Geyer
November 2018, Blood advances,
Christoph Kannicht, and Ilona Danßmann, and Constanze Weilandt, and Katja Derkow, and Guido Kohla, and Henriette Geyer
September 2016, Haemophilia : the official journal of the World Federation of Hemophilia,
Christoph Kannicht, and Ilona Danßmann, and Constanze Weilandt, and Katja Derkow, and Guido Kohla, and Henriette Geyer
January 2024, Frontiers in immunology,
Christoph Kannicht, and Ilona Danßmann, and Constanze Weilandt, and Katja Derkow, and Guido Kohla, and Henriette Geyer
October 2001, Cellular immunology,
Christoph Kannicht, and Ilona Danßmann, and Constanze Weilandt, and Katja Derkow, and Guido Kohla, and Henriette Geyer
January 2015, PloS one,
Christoph Kannicht, and Ilona Danßmann, and Constanze Weilandt, and Katja Derkow, and Guido Kohla, and Henriette Geyer
January 2015, Clinical pharmacology in drug development,
Christoph Kannicht, and Ilona Danßmann, and Constanze Weilandt, and Katja Derkow, and Guido Kohla, and Henriette Geyer
March 2008, Arteriosclerosis, thrombosis, and vascular biology,
Christoph Kannicht, and Ilona Danßmann, and Constanze Weilandt, and Katja Derkow, and Guido Kohla, and Henriette Geyer
April 2019, International journal of laboratory hematology,
Christoph Kannicht, and Ilona Danßmann, and Constanze Weilandt, and Katja Derkow, and Guido Kohla, and Henriette Geyer
January 2020, Frontiers in immunology,
Christoph Kannicht, and Ilona Danßmann, and Constanze Weilandt, and Katja Derkow, and Guido Kohla, and Henriette Geyer
June 2011, Molecular & cellular proteomics : MCP,
Copied contents to your clipboard!